Bellevue Group AG Sells 5,000 Shares of ADMA Biologics, Inc. (NASDAQ:ADMA)

Bellevue Group AG reduced its stake in ADMA Biologics, Inc. (NASDAQ:ADMA) by 16.2% during the third quarter, Holdings Channel.com reports. The institutional investor owned 25,900 shares of the biotechnology company’s stock after selling 5,000 shares during the period. Bellevue Group AG’s holdings in ADMA Biologics were worth $518,000 as of its most recent filing with the SEC.

Other institutional investors also recently added to or reduced their stakes in the company. USA Financial Formulas raised its stake in shares of ADMA Biologics by 8.6% in the third quarter. USA Financial Formulas now owns 6,817 shares of the biotechnology company’s stock valued at $136,000 after buying an additional 539 shares during the period. Vontobel Holding Ltd. boosted its stake in ADMA Biologics by 7.0% during the third quarter. Vontobel Holding Ltd. now owns 13,643 shares of the biotechnology company’s stock valued at $273,000 after buying an additional 888 shares during the period. Hollencrest Capital Management purchased a new position in shares of ADMA Biologics during the third quarter worth about $30,000. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of ADMA Biologics by 21.8% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 8,430 shares of the biotechnology company’s stock worth $163,000 after purchasing an additional 1,509 shares in the last quarter. Finally, Larson Financial Group LLC bought a new position in shares of ADMA Biologics in the third quarter worth approximately $31,000. Institutional investors own 75.68% of the company’s stock.

Insider Transactions at ADMA Biologics

In related news, CFO Brad L. Tade sold 15,000 shares of the stock in a transaction on Friday, November 22nd. The stock was sold at an average price of $21.15, for a total transaction of $317,250.00. Following the sale, the chief financial officer now directly owns 199,433 shares of the company’s stock, valued at $4,218,007.95. This trade represents a 7.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Lawrence P. Guiheen sold 9,000 shares of the business’s stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $18.47, for a total value of $166,230.00. Following the completion of the transaction, the director now directly owns 153,941 shares of the company’s stock, valued at approximately $2,843,290.27. This trade represents a 5.52 % decrease in their position. The disclosure for this sale can be found here. Insiders own 3.70% of the company’s stock.

ADMA Biologics Price Performance

ADMA stock opened at $20.11 on Monday. The company has a debt-to-equity ratio of 0.48, a current ratio of 7.09 and a quick ratio of 3.26. ADMA Biologics, Inc. has a 1 year low of $3.60 and a 1 year high of $23.64. The firm has a 50-day moving average of $19.08 and a 200 day moving average of $15.40. The company has a market cap of $4.75 billion, a P/E ratio of 71.82 and a beta of 0.64.

ADMA Biologics (NASDAQ:ADMA) last announced its earnings results on Thursday, November 7th. The biotechnology company reported $0.15 EPS for the quarter, beating analysts’ consensus estimates of $0.13 by $0.02. ADMA Biologics had a net margin of 17.80% and a return on equity of 53.20%. The firm had revenue of $119.84 million for the quarter, compared to analysts’ expectations of $107.25 million. During the same quarter in the previous year, the business posted $0.01 EPS. On average, sell-side analysts forecast that ADMA Biologics, Inc. will post 0.52 EPS for the current year.

Analyst Ratings Changes

Several equities research analysts have issued reports on ADMA shares. HC Wainwright lifted their target price on shares of ADMA Biologics from $18.00 to $26.00 and gave the company a “buy” rating in a research report on Friday, November 8th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $20.00 price objective on shares of ADMA Biologics in a report on Friday, September 20th. Finally, Raymond James upped their target price on shares of ADMA Biologics from $18.00 to $25.00 and gave the stock a “strong-buy” rating in a research report on Friday, November 8th.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.